Long-term prediction of cardiovascular outcomes by circulating CD34+ and CD34+CD133+ stem cells in patients with type 2 diabetes

Diabetes Care

Volumn 40, Issue 1, 2017, Pages 125-131

  Fadini, Gian Paolo ^a   Rigato, Mauro ^a   Cappellari, Roberta ^a   Bonora, Benedetta Maria ^a   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CD133 ANTIGEN; CD34 ANTIGEN; INCRETIN; INSULIN; METFORMIN; BIOLOGICAL MARKER; PROM1 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD34+ CD133+ STEM CELL; CD34+ STEM CELL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PREDICTION; RISK ASSESSMENT; STEM CELL; BLOOD; CARDIOVASCULAR DISEASES; CELL COUNT; COMPLICATION; EVALUATION STUDY; IMMUNOLOGY; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK FACTOR; VERY ELDERLY;

AC133 ANTIGEN; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BIOMARKERS; CARDIOVASCULAR DISEASES; CELL COUNT; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; STEM CELLS;

EID: 85008194271     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1755     Document Type: Article

References (33)

1. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc 2012;1: 8-15
2. Boyko EJ, Meigs JB. Does diabetes always confer coronary heart disease risk equivalent to a prior myocardial infarction?: implications for prevention. Diabetes Care 2011;34:782-784
3. Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005;45: 1449-1457
4. Egan CG, Lavery R, Caporali F, et al. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 2008;51:1296-1305
5. Hernandez SL, Gong JH, Chen L, et al. Characterization of circulating and endothelial progenitor cells in patients with extreme-duration type 1 diabetes. Diabetes Care 2014;37:2193-2201
6. Henry TD, Schaer GL, Traverse JH, et al.; ACT. Autologous CD34(+) cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant 2016;25:1701-1711
7. LosordoDW, Kibbe MR, Mendelsohn F, et al.; Autologous CD34+ Cell Therapy for Critical Limb Ischemia Investigators. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012;5:821-830
8. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003;101:168-172
9. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006;98:e20-e25
10. Lanuti P, Rotta G, Almici C, et al. Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood. Cytometry A 2016;89:259-270
11. Case J, Mead LE, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007;35: 1109-1118
12. Pozzoli O, Vella P, Iaffaldano G, et al. Endothelial fate and angiogenic properties of human CD34+ progenitor cells in zebrafish. Arterioscler Thromb Vasc Biol 2011;31:1589-1597
13. Hayek SS, MacNamara J, Tahhan AS, et al. Circulating progenitor cells identify peripheral arterial disease in patients with coronary artery disease. Circ Res 2016;119:564-571
14. Patel RS, Li Q, Ghasemzadeh N, et al. Circulating CD34+ progenitor cells and risk of mortality in a population with coronary artery disease. Circ Res 2015;116:289-297
15. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353: 999-1007
16. Rigato M, Avogaro A, Fadini GP. Levels of circulating progenitor cells, cardiovascular outcomes and death: A meta-analysis of prospective observational studies. Circ Res 2016;118: 1930-1939
17. Fadini GP, Maruyama S, Ozaki T, et al. Circulating progenitor cell count for cardiovascular risk stratification: A pooled analysis. PLoS One 2010;5:e11488
18. Rigato M, Bittante C, Albiero M, Avogaro A, Fadini GP. Circulating progenitor cell count predicts microvascular outcomes in type 2 diabetic patients. J Clin Endocrinol Metab 2015;100: 2666-2672
19. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212
20. Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol 2016;15:111
21. Makino H, Miyamoto Y, Kikuchi-Taura A, Soma T, Taguchi A, Kishimoto I. Decreased levels of circulating CD34(+) cells are associated with coronary heart disease in Japanese patients with type 2 diabetes. J Diabetes Investig 2015; 6:473-478
22. Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 2012;110:624-637
23. Madeddu P, Emanueli C, Pelosi E, et al. Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J 2004;18:1737-1739
24. Cappellari R, D'Anna M, Avogaro A, Fadini GP. Plerixafor improves the endothelial health balance. The effect of diabetes analysed by polychromatic flow cytometry. Atherosclerosis 2016;251:373-380
25. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101: 671-679
26. Al Mheid I, Corrigan F, Shirazi F, et al. Circadian variation in vascular function and regenerative capacity in healthy humans. J Am Heart Assoc 2014;3:e000845
27. Fadini GP, Boscaro E, de Kreutzenberg S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010;33: 1097-1102
28. Fiorina P, Jurewicz M, Vergani A, et al. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol 2011;186:121-131
29. Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 Investigators. Allogeneic mesenchymal precursor cells in type 2 diabetes: A randomized, placebo-controlled, dose-escalation safety and tolerability pilot study. Diabetes Care 2015;38:1742-1749
30. D'Addio F, Valderrama Vasquez A, Ben Nasr M, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: amulticenter analysis. Diabetes 2014;63:3041-3046
31. van der Valk FM, Kuijk C, Verweij SL, et al. Increased haematopoietic activity in patients with atherosclerosis. Eur Heart J. 29 June 2016 [Epub ahead of print]. DOI: http://dx.doi.org/10.1093/eurheartj/ehw246
32. Al Mheid I, Hayek SS, Ko YA, et al. Age and human regenerative capacity impact of cardiovascular risk factors. Circ Res 2016;119:801-809
33. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med 2011;364:829-841